Elevation Oncology Inc (NAS:ELEV)
$ 3.84 0.15 (4.07%) Market Cap: 209.81 Mil Enterprise Value: 136.57 Mil PE Ratio: 0 PB Ratio: 2.62 GF Score: 24/100

Elevation Oncology Inc at Cowen Health Care Conference Transcript

Mar 07, 2023 / 05:50PM GMT
Release Date Price: $1.35 (-2.88%)
Unidentified Analyst

(technical difficulty) analyst at GI/GU oncology panel, and with us, we have six companies. I'm just going to introduce them one by one in alphabetical order. We have Daniel O'Connor from Ambrx; we have Mark Erlander from Cardiff; we have Joe Ferra from Elevation Oncology; we have Scott Koenig from MacroGenics; Joe McCann from POINT Biopharma; and Liz Barrett from UroGen. Thank you, everybody, for joining us.

Questions & Answers

Unidentified Analyst;Liz Barrett

In terms of the format, we're going to ask maybe two general questions to the panelists, and then we're going to go round robin with specific company-focused questions. So first question is in GI/GU, oncology includes obviously a wide range of tumor types, each of which has unique development considerations. However, there are some regulatory factors that broadly apply to all these tumors. And I'll start with Project Optimus, how are you incorporating that in your clinical development?

So maybe let's just start with, I guess, the left side of the table.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot